Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Pharmaron Beijing Co's Days Payable or its related term are showing as below:
FRA:17Q1'
s Days Payable Range Over the Past 10 Years
Min: 16.17 Med: 19.03 Max: 21.53
Current: 21.5
During the past 12 years, Pharmaron Beijing Co's highest Days Payable was 21.53. The lowest was 16.17. And the median was 19.03.
FRA:17Q1's Days Payable is ranked worse than 87.61% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs FRA:17Q1: 21.50
Pharmaron Beijing Co's Days Payable
increased
from Mar. 2025 (21.63) to Mar. 2026 (22.93).
It may suggest that Pharmaron Beijing Codelayed paying its suppliers.
Pharmaron Beijing Co Days Payable Related Terms
Pharmaron Beijing Co Days Payable Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:17Q1 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharmaron Beijing Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (FRA:17Q1) has a Days Payable of 22.93 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmaron Beijing Co and its competitors. This is 20% above median its historical median of 19.03. Over the past decade, Pharmaron Beijing Co's Days Payable has ranged from 16.17 to 21.53. According to the industry distribution chart, Pharmaron Beijing Co ranks #615 out of 702 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Pharmaron Beijing Co's Days Payable too high?
Pharmaron Beijing Co's current Days Payable of 22.93 is 20% above median its 10-year median of 19.03. Over the past 10 years, this metric has ranged from a low of 16.17 to a high of 21.53. The Biotechnology industry median Days Payable is 113.10. Pharmaron Beijing Co's value of 22.93 is 79.7% below this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #615 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #615 out of 702 companies for Days Payable. This places Pharmaron Beijing Co in the lower half of its industry. The industry median Days Payable is 113.10. Pharmaron Beijing Co's value of 22.93 is 79.7% below this benchmark. Historically, Pharmaron Beijing Co's own Days Payable has ranged from 16.17 to 21.53 over the past decade. While the company's 10-year median is 19.03 vs. the industry median of 113.10, Pharmaron Beijing Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current Days Payable of 22.93 is 79.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current Days Payable is 22.93, which is 20% above median its own 10-year median of 19.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (FRA:17Q1) has a current Days Payable of 22.93. The stock's GF Value™ is €2.23, compared to a current price of €2.58 — trading 15.7% above its estimated fair value. The current Days Payable is 22.93, which is 20% above median its 10-year median of 19.03 and 79.7% below the Biotechnology industry median of 113.10. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharmaron Beijing Co (FRA:17Q1), the current Days Payable is 22.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (FRA:17Q1) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of €2.58 is trading 15.7% above its estimated GF Value™ of €2.23.
Key valuation signals for FRA:17Q1:
Days Payable: 22.93 (20% above median its 10-year median of 19.03)
GF Value™: €2.23 vs. price of €2.58 (15.7% above fair value)
Industry Position: 79.7% below the Biotechnology median (#615 of 702)
No single metric tells the full story. See the FRA:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for FRA:17Q1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17Q1 has been successfully added to your 
